Volume 19, Number 10—October 2013
Dispatch
Primary Multidrug-Resistant Mycobacterium tuberculosis in 2 Regions, Eastern Siberia, Russian Federation
Svetlana Zhdanova1, Scott K. Heysell1
, Oleg Ogarkov, Galina Boyarinova, Galina Alexeeva, Suporn Pholwat, Elena Zorkaltseva, Eric R. Houpt, and Eugeniy Savilov
, Oleg Ogarkov, Galina Boyarinova, Galina Alexeeva, Suporn Pholwat, Elena Zorkaltseva, Eric R. Houpt, and Eugeniy Savilov
Table 2
Resistance mutations in Mycobacterium tuberculosis from 51 patients from Irkutsk and Yakutia, Russian Federation*
| Drug, locus |
Mutation, no. (% total) | Drug resistance, no. (% with mutation) |
|
|---|---|---|---|
| Amino acid change |
Nucleotide change |
||
| Isoniazid | |||
| katG | Ser315Thr 28 (55) | 25 (89) | |
| Ser315Thr/Trp321Cys 4 (7) | 4 (100) | ||
| Trp321Cys 1 (2) | 1 (100) | ||
| Thr322Ala 1 (2) | 0 | ||
| No mutation 8 (16) | 3 (38) | ||
| No amplification 9 (18) | 8 (89) | ||
| inhA | C(−15)T 3 (6) | 3 (100) | |
| T(−8)A 1 (2) | 1 (100) | ||
| G (−13)T 1 (2) | 1 (100) | ||
| No mutation 41 (80) | 32 (78) | ||
| No amplification 4 (7) | 4 (100) | ||
| Rifampin, rpoB | Ser531Leu 19 (37) | 15 (79) | |
| Ser531Leu/Thr481Ala 1 (2) | 0 | ||
| Ser 531Leu/Thr480Ile 2 (4) | 2 (100) | ||
| Ser531Tryp/Val456Gly 1 (2) | 1 (100) | ||
| Gln513Lys 2 (4) | 2 (100) | ||
| Leu533Pro 1 (2) | 1 (100) | ||
| His516Tyr 1 (2) | 1 (100) | ||
| Leu511Pro 1 (2) | 0 | ||
| No mutation 22 (43) | 6 (27) | ||
| No amplification 1 (2) | 0 | ||
| Fluoroquinolones, gyrA | Not performed | ||
| Ser95Thr 46 (90)† | |||
| Asp94Gly 1 (2) | |||
| Asp94Ala 1 (2) | |||
| Ala90Val 1 (2) | |||
| No amplification 2 (4) | |||
| Ethambutol, embB | Asp354Ala 3 (6) | 1 (33) | |
| Asp354Ala/Gly406Asp 1 (2) | 0 | ||
| Met306Val 3 (6) | 3 (100) | ||
| Met306Ile 3 (6) | 3 (100) | ||
| Gly406Ser 3 (6) | 2 (67) | ||
| Gly406Ala 2 (4) | 0 | ||
| Gly406Cyst 1 (2) | 1 (100) | ||
| No mutation 25 (49) | 9 (36) | ||
| No amplification 10 (20) | 3 (30) | ||
| Not performed | |||
| Pyrazinamide, pncA‡ | Gly113Phe 3 (6)§ | G338T and C96T | |
| Leu19Arg 2 (4)§ | T56G | ||
| Gly113Phe/Arg121 Leu 1 (2)§ | G338T and C96T/ G362T | ||
| Arg121Leu 1(2)§ | G362T | ||
| Gln10Pro 1 (2) | A29C | ||
| Val7Gly 1 (2) | T20G /G481C | ||
| Ala161Pro/ Val155Ala 1 (2)§ | G203A | ||
| His137Asp/ Frameshift 1 (2)§ | T464C/ insertion C480 | ||
| Tryp68Stop 1 (2)§ | C409G | ||
| Frameshift 1 (2)§ | deletionG5 | ||
| No mutation 8 (14) | |||
| No amplification 30 (59) | |||
| Kanamycin | |||
| rrs | A1401G 4 (57) | 3 (75) | |
| C1443G 3 (43) | 1 (33) | ||
| No mutation 35 | 12 (34) | ||
| No amplification 9 | 3 (33) | ||
| eis | G(−10)A 4 (44) | 2 (50)¶ | |
| C(−14)T 1 (11) | 1 (100)¶ | ||
| C(−15)G 2 (22) | 0 | ||
| C(−14)G 1 (11) | 0 | ||
| C(−12)T 1 (11) | 0 | ||
| No mutation 36 | 11 | ||
| No amplification 6 | 3 (50) | ||
*Blank cells indicate not applicable. All inhA mutations were associated with a Ser315Thr mutation in katG except for 1 isolate in which katG did not amplify.
†Previously demonstrated not to be associated with phenotypic resistance.
‡Excluding 25 silent pncA mutations (Ser32Ser most common, n = 14).
§Mutations in pncA not previously reported. Conventional susceptibility testing was unavailable for pyrazinamide and the fluoroquinolones.
¶For all 3 mutations of eis associated with kanamycin resistance, rrs was wild type.
1These authors contributed equally to this article.
Page created: September 16, 2013
Page updated: September 16, 2013
Page reviewed: September 16, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.